Delivery Order SPE2DB20D3505-SPE2DB21FT7U5
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,700.64 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,270.98 Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,148.69 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,577.25 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. The IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,846.99, is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc. The IDC, worth up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,758.46 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty...
- This federal contract award, valued at $17,067.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the DLA's Indefinite Delivery Contract (IDC) with Amerisourcebergen, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,497.67 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $23,281.60 and issued by the Defense Logistics Agency (DLA) under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans'...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,931.16 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB21FT7U5Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,797.92 delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract covers a broad spectrum of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. This award was not designated with any set-aside requirements, indicating open competition. Amerisourcebergen is a subsidiary of the parent company Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation valued at up to $750,000 through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 3/4/21 |